Most recently released targets
In the race to the next big breakthrough you need to have the best tools available. We are constantly working to keep pace with the speed of your innovation to provide you with the products you need.
In the race to the next big breakthrough you need to have the best tools available. We are constantly working to keep pace with the speed of your innovation to provide you with the products you need.
New assays are available in AlphaLISA™ SureFire® Ultra™, AlphaLISA™, and HTRF™ technologies within several different therapeutic areas and research fields.
- Cardiovascular: eNOS Phospho-S1177, Phospho-T495, Total
- Inflammation: PI3K p85 Phospho-Y467, RIPK1 Phospho-S320, Phospho-S321
- Neurodegenerative Disease: PERK Phospho-T982
- Oncology: BAD Phospho-S112, Phospho-S236, Cleaved PARP1 N214, MEK2 Phospho-S217/221, PRAS40 Phospho-T246, Progesterone Receptor Phospho-S190, Rb Phospho-T821, Phospho-T826, RNA Polymerase Phospho-S2, Phospho-S5
- Targeted Protein Degradation – Inflammation: NFkB2 p100 Total, NFkB2 p100/p52 Total, PI3K p85 Total, RIPK1 Total, TRAF3 Total
- Targeted Protein Degradation – Oncology, BAD Total, CK1 Alpha Total, MEK2 Total, p16 INK14A Total, p21 CiP1 Total, PRAS40 Total, Progesterone Receptor Total, RNA Polymerase Total, SALL4 Total
Newest target videos
Discover brief animated videos providing information on specific targets and research areas that are addressed by our newly released assay kits!
Discover brief animated videos providing information on specific targets and research areas that are addressed by our newly released assay kits!
Targeting tau proteins
Aurora kinases in the cell cycle
The power of cytokines
Autophagy and its potential in therapeutics
HTT in Huntington’s disease pathology
AAVs as gene therapy vectors
Exploring Janus kinases
BRD proteins as therapeutic targets
LC3B: Key marker of autophagy
Targeting the ECM
Explore Alpha, HTRF, LANCE Ultra, and DELFIA assay technologies
Our Alpha, HTRF®, LANCE® Ultra™ TR-FRET, and DELFIA® TRF technologies offer alternatives to standard ELISA assay kits, each with a larger dynamic range and higher signal-to-noise ratio. Alpha, HTRF and LANCE Ultra TR-FRET have the added advantage of having no wash or separation steps, saving you valuable time. Discover sandwich assays, protein detection assays, cell based assays, and more!
Our Alpha, HTRF®, LANCE® Ultra™ TR-FRET, and DELFIA® TRF technologies offer alternatives to standard ELISA assay kits, each with a larger dynamic range and higher signal-to-noise ratio. Alpha, HTRF and LANCE Ultra TR-FRET have the added advantage of having no wash or separation steps, saving you valuable time. Discover sandwich assays, protein detection assays, cell based assays, and more!
Alpha is a bead-based, no-wash luminescent technology. When Alpha Donor and Acceptor beads are brought together through binding to the target, a cascade of chemical reactions is set in motion, creating an amplified signal. These versatile beads are conjugated with various biomolecules that enable the detection of unique biological events, offering maximum flexibility.
HTRF (Homogeneous Time Resolved Technology) is a FRET-based, no-wash technology. HTRF technology is rapid, homogeneous, easy to use and to automate, allows extreme miniaturization and easy assay development. HTRF technology can be used in competitive and noncompetitive formats, performed as cellular or biochemical assays, and thus can been applied to a variety of applications.
LANCE (Lanthanide Chelate Excite) Ultra TR-FRET is a no wash proximity assay that combines the benefits of time resolution (TR) with fluorescence resonance energy transfer (FRET) principles by using energy donor and energy acceptor fluorophore labels.
DELFIA (dissociation-enhanced lanthanide fluorescence immunoassay) is a time-resolved fluorescence (TRF) intensity technology. DELFIA has a similar assay principle and workflow to that of a traditional ELISA, but with the added benefits of a stable, time-resolved fluorescent signal improving assay dynamic range. DELFIA also offers a multiplexing capability.
